> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-163/
- Published: 2018-01-21T12:00:00.000Z
- Updated: 2026-09-14T23:15:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140557

[**Draft Guide on Expedited Notifications on Product Recalls**](https://www.fdaweb.com/draft-guide-on-expedited-notifications-on-product-recalls/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Public Warning and Notification of Recalls Under 21 CFR Part 7, Subpart C.” 01/19/2018

[**Draft Guide on Medical Countermeasure Voucher Program**](https://www.fdaweb.com/draft-guide-on-medical-countermeasure-voucher-program/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Material Threat Medical Countermeasure Priority Review Vouchers.” 01/19/2018

[**Debarment Ordered in Unapproved Drugs Case**](https://www.fdaweb.com/debarment-ordered-in-unapproved-drugs-case/)  
*Federal Register* notice: FDA permanently debars William Ralph Kincaid from providing services in any capacity to a person that has an approved or pending drug product application. 01/18/2018

[**Regulatory Review Period for Forest Labs’ Avycaz**](https://www.fdaweb.com/regulatory-review-period-for-forest-labs-avycaz/)  
*Federal Register* notice: FDA determines for patent extension purposes that the regulatory review period for Forest Laboratories’ Avycaz (ceftazidime pentahydrate and avibactam sodium) was 2,579 days. 01/18/2018

[**FDA Withdraws 22 ANDAs No Longer Marketed**](https://www.fdaweb.com/fda-withdraws-22-andas-no-longer-marketed/)  
*Federal Register* notice: FDA withdraws approval of 22 ANDAs from multiple applicants. 1/17/2018

[**Proposed Rule on CDRH Supervisory Review of Certain Actions**](https://www.fdaweb.com/proposed-rule-on-cdrh-supervisory-review-of-certain-actions/)  
*Federal Register* proposed rule: FDA proposes to implement regulations regarding internal agency supervisory review of certain decisions related to devices regulated by CDRH. 01/17/2018

[**OMB Approval Sought for Genomic Test Info Collection**](https://www.fdaweb.com/omb-approval-sought-for-genomic-test-info-collection/)  
*Federal Register* notice: FDA submits for OMB clearance a new information collection entitled “Use of Public Human Genetic Variant Databases To Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics — OMB Control Number 0910.” 01/17/2018

[**Guide on UDI Enforcement Discretion for Certain Devices**](https://www.fdaweb.com/guide-on-udi-enforcement-discretion-for-certain-devices/)  
*Federal Register* notice: FDA makes available a guidance entitled “Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices.” 01/16/2018

[**Workshop on Device Conformity Assessment to Recognized Standards**](https://www.fdaweb.com/workshop-on-device-conformity-assessment-to-recognized-standards/)  
*Federal Register* notice: FDA announces a 5/22-23 public workshop on “Accreditation Scheme for Conformity Assessment of Medical Devices to FDA-Recognized Standards.” 01/16/2018